Stage IV prostate cancer at 52. No symptoms. PSA 4,056 → undetectable. NICE Patient Expert. Founder, Smart As Daddy. If you think you’re too young — so did I.
£25 million a year to screen the highest-risk men. £4.5 billion to treat the men diagnosed too late. The NSC looked at those numbers and said no. That’s not a clinical decision. That’s a policy failure.
@CliveJonesMP Well done, Clive. A plan that has to report to Parliament every year is a plan that has to deliver. For men like me, diagnosed at Stage 4 with no prostate cancer symptoms, the number to watch is how many are still found too late.
@ConversationUS 'Benefits outweigh harms' is the evidence base UK policy still hasn't absorbed. PCRMP — the GP risk-stratification tool — was withdrawn earlier this year, leaving family-history men like me with no structured route in. ACS is moving the right way.
@OncoDailyGU@Adam_Weiner535 Important move from ACS. The UK went the other way earlier this year — PCRMP withdrawn, nothing structured left for GPs to risk-stratify. Worth a look at how the evidence bases compare.
@ProstateUK The June programme covers a few thousand BRCA2 carriers. Meanwhile nearly half of UK diagnoses are already Stage 3 or 4 — around 30,000 men a year. That's the gap TRANSFORM can't close in the time it takes to report.
@ProstateUK Thanks Mel. TRANSFORM is vital work. The harder question is what high-risk men do in the meantime — first-degree family history, Black men, under-50s. An interim risk-stratified pathway while TRANSFORM reports would save lives now.
@ProstateUK@jcrfear Agreed. The gap isn't about evidence any more — it's about speed. Risk-stratified PSA pathways are already being piloted elsewhere. Every year the UK waits, families like mine pay the cost.
@PCR_News@DavidLammy Real signal of intent from PCR. The inequalities picture here is stark — Black men 1 in 4 vs 1 in 8, late diagnosis in deprived areas. Hopeful this unlocks the political traction we've been missing on earlier detection.
@DrIanWeissman Biennial from 50, annual from 45 for high-risk — same evidence base on both sides of the Atlantic. The UK just removed the primary-care tool that supported that conversation at the GP. The clinical case didn't change; the policy did.
@ZEROCancer@ACSNews The 45 trigger for Black men and first-degree family history is the exact position UK advocates have been pushing. Instead, the UK withdrew the PCRMP this year — the primary-care tool that supported those conversations at the GP. We've moved the wrong way.
@PCR_News@macmillancancer Early diagnosis and inequalities are the two levers that would have caught cases like mine before Stage 4. Good to see PCR and Macmillan pulling on both together.
@BinaPattel Prostate the most common and still no national screening programme. The PCRMP risk-stratification tool was withdrawn earlier this year — primary care has less, not more, to work with.
@OncoDailyGU@fcounago Early detection leading the agenda at EMUC26 lands at a useful moment. The UK went the other way this year when PCRMP was withdrawn, and the case for structured, risk-stratified GP access needs rebuilding.
@fcounago Good to see screening and early detection on the EMUC26 agenda. The UK moved the other way this year when PCRMP was withdrawn, and men diagnosed at T4 with a first-degree family history, like me, are pressing to get structured GP access back.
@PCR_News@John2Win@RishiSunak The timetable matters because of the asymmetry behind it. NICE approves late-stage prostate drugs at up to £35k per QALY. The Screening Committee judges earlier detection against £20k. Same disease, same NHS, two budget lines, and prevention loses every time.
@PCR_News@DrScottArthurMP Two men with identical risk profiles, two different outcomes depending on postcode and which GP they happen to see. A pathway that relies on chance and persistence is a pathway that widens the gap, not closes it.
@PCR_News@IanSollom Risk-stratified PSA for high-risk men would pay for itself before you start counting the lives. The numbers only look expensive if you ignore what late-stage treatment already costs.
@PCR_News@John2Win The four questions in order of weight: transparency first, PSA access second, BRCA2 third, evidence reviews on a clock. Anything else and the Government gets to define its own homework.
@JUrology 15% uptake says more about delivery than idea. With the PCRMP risk-stratification tool withdrawn in England, anything that helps GPs handle PSA conversations without overwhelming primary care is worth a closer look. What blocked uptake — awareness or access?
@NBCDigitalNews Stage 2 caught early is what the whole pathway should be optimised for. Diagnosed Stage 4 at 52 in the UK after symptoms, no screening conversation — early detection has to be the default, not the exception.